# Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

> **NCT06804096** · PHASE4 · RECRUITING · sponsor: **Dr. Md. Alimur Reza** · enrollment: 160 (estimated)

## Conditions studied

- Pneumonia, Community-Acquired
- Bacterial Pneumonia

## Interventions

- **DRUG:** Faropenem
- **DRUG:** Co-amoxiclav
- **DRUG:** Clarithromycin 500 mg

## Key facts

- **NCT ID:** NCT06804096
- **Lead sponsor:** Dr. Md. Alimur Reza
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06804096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06804096, "Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06804096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*